NCT07182526 Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
| NCT ID | NCT07182526 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Al-Mustansiriyah University |
| Condition | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-09-20 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2025-09-20 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
Eligibility Criteria
Inclusion Criteria: * • Newly diagnosed patients should be at reproductive aged from 18-40 years. * Patients diagnosed with presence of micro polycystic ovaries at ultrasound. * Oligomenorrhea with inter-menstrual intervals longer than 35 days. * Clinical or biochemical signs of hyperandrogenism (acne, hirsutism). * Normal PRL levels. Exclusion Criteria: * • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes. * Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction). * Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs. * Pregnant women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07182526 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07182526 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07182526 currently recruiting?
Yes, NCT07182526 is actively recruiting participants. Contact the research team at pharm.drmhdclinical@uomustansiriyah.edu.iq for enrollment information.
Where is the NCT07182526 trial being conducted?
This trial is being conducted at Baghdad, Iraq.
Who is sponsoring the NCT07182526 clinical trial?
NCT07182526 is sponsored by Al-Mustansiriyah University. The trial plans to enroll 150 participants.